5 April 2018 - - Summit, New Jersey-based cancer and inflammatory disease treatment developer Celgene Corp. (NASDAQ: CELG) president and chief operating officer, Scott A. Smith, is leaving the company, effective immediately, and his primary responsibilities will be assumed by chairman and chief executive officer Mark J. Alles,.
In addition to existing responsibilities, Alles will be responsible for strategic leadership of Celgene's global hematology and oncology franchise, global inflammation and immunology franchise, manufacturing, regulatory, and clinical development.
Scott served as president and COO starting in April 2017. He joined Celgene in 2008 and has held several senior positions.
Celgene is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.